OSLO, Norway, and
HELSINKI, April 22, 2020 /PRNewswire/ -- Targovax
ASA (OSE: TRVX), a clinical stage immuno-oncology company
developing oncolytic viruses and cancer vaccines to target
hard-to-treat solid tumors, and Valo Therapeutics (Valo Tx) today
announce that they have entered into a collaboration agreement to
evaluate PeptiCRAd technology as a tool to coat ONCOS oncolytic
adenoviruses with Targovax's TG mutant RAS peptides.
Valo Tx's PeptiCRAd technology has been developed to coat
oncolytic viruses with tumor antigen peptides for enhanced immune
activation and local delivery of antigens directly into the tumor
site. With this collaboration, Targovax and Valo Tx will test
whether PeptiCRAd coating of ONCOS-102 adenovirus with TG mutant
RAS peptides can generate enhanced systemic CD4+ and CD8+ T-cell
responses against mutant RAS, and specifically direct these T-cells
to the tumor site.
The technical feasibility, in vitro activity and in
vivo immune activation potential of the concept will be
evaluated in the first phase of the collaboration. If successful,
the parties will jointly determine how to further expand and
develop the collaboration to establish a first-in-class oncolytic
virus engineered to induce mutant RAS immune
responses.
Dr. Anne-Sophie Møller, Head of Clinical Science of Targovax,
said: "We are excited to initiate this collaboration with Valo
Therapeutics. We continue to view mutant RAS as a very compelling
immunotherapeutic target. The innovative PeptiCRAd technology
enables us to merge our peptide vaccine and oncolytic virus
platforms to generate a truly novel RAS-targeting ONCOS vaccine.
The combination of these promising technologies could become a new
platform supporting our aspiration to develop novel therapies for
hard-to-treat solid tumors."
Dr. Sari Pesonen, Head of
R&D at Valo Tx, commented, "We are delighted that Targovax
has chosen to partner with us in the solid tumor space, providing
further endorsement of our PeptiCRAd technology. By enabling the
coating of ONCOS-102 adenovirus with TG mutant RAS peptides, we
have a unique opportunity to take full advantage of the clinically
proven immune activation potency of ONCOS-102 by directing the
immune responses towards mutant RAS neoantigens, driving enhanced
tumor-specific T-cell responses in cancer patients."
CONTACT:
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruse,c3093798
View original
content:http://www.prnewswire.com/news-releases/targovax-and-valo-therapeutics-enter-collaboration-to-develop-ras-neoantigen-coating-of-oncos-viruses-using-pepticrad-technology-301044964.html
SOURCE Targovax